BridgeBio Pharma Inc. (BBIO)
undefined
undefined%
At close: undefined
27.49
-0.04%
After-hours Dec 13, 2024, 04:15 PM EST

Company Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.

The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.

Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones.

In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases.

BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc.

The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.
BridgeBio Pharma Inc. logo
Country United States
IPO Date Jun 27, 2019
Industry Biotechnology
Sector Healthcare
Employees 550
CEO Dr. Neil Kumar Ph.D.

Contact Details

Address:
421 Kipling Street
Palo Alto, California
United States
Website https://www.bridgebio.com

Stock Details

Ticker Symbol BBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001743881
CUSIP Number 10806X102
ISIN Number US10806X1028
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Eric Michael David J.D., M.D., Ph.D. Chief Executive Officer of Gene Therapy
Dr. Neil Kumar Ph.D. Co-Founder, Chief Executive Officer & Director
Dr. Brian C. Stephenson C.F.A., Ph.D. Chief Financial Officer & Secretary
Dr. Thomas Trimarchi Ph.D. President & Chief Operating Officer
Dr. Charles J. Homcy M.D. Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Frank P. McCormick Ph.D. Co-Founder, Chairman of Oncology & Director
Dr. Richard H. Scheller Ph.D. Chairman of Research & Development
Dr. Uma Sinha Ph.D. Chief Scientific Officer
Eli M. Wallace Ph.D. Chief Scientific Officer of Oncology
Grace Rauh Vice President of Communications

Latest SEC Filings

Date Type Title
Dec 12, 2024 4 Filing
Dec 12, 2024 4 Filing
Dec 12, 2024 4 Filing
Nov 25, 2024 8-K Current Report
Nov 20, 2024 4 Filing
Nov 20, 2024 4 Filing
Nov 19, 2024 4 Filing
Nov 19, 2024 4 Filing
Nov 19, 2024 4 Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...